aTyr Pharma (NASDAQ:LIFE) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of aTyr Pharma (NASDAQ:LIFE) in a research report report published on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

LIFE has been the topic of a number of other reports. HC Wainwright reaffirmed a buy rating and issued a $35.00 price objective on shares of aTyr Pharma in a research note on Tuesday, May 14th. Royal Bank of Canada decreased their price objective on shares of aTyr Pharma from $19.00 to $16.00 and set an outperform rating for the company in a report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, aTyr Pharma currently has a consensus rating of Hold and a consensus target price of $23.67.

aTyr Pharma Price Performance

The company has a market capitalization of $131.12 million, a price-to-earnings ratio of -2.11 and a beta of 1.19. aTyr Pharma has a 12 month low of $1.08 and a 12 month high of $2.45. The business’s 50-day moving average is $1.76 and its two-hundred day moving average is $1.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.07.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.11 million. On average, equities analysts predict that aTyr Pharma will post -0.89 earnings per share for the current year.

Insider Transactions at aTyr Pharma

In other news, CEO Sanjay Shukla bought 20,000 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The shares were bought at an average cost of $1.81 per share, with a total value of $36,200.00. Following the completion of the purchase, the chief executive officer now directly owns 136,548 shares in the company, valued at $247,151.88. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CEO Sanjay Shukla bought 20,000 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The shares were bought at an average cost of $1.81 per share, with a total value of $36,200.00. Following the completion of the purchase, the chief executive officer now directly owns 136,548 shares in the company, valued at $247,151.88. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Timothy Coughlin bought 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was purchased at an average cost of $1.75 per share, for a total transaction of $87,500.00. Following the completion of the purchase, the director now owns 56,000 shares of the company’s stock, valued at $98,000. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 75,000 shares of company stock worth $132,650. 3.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Granite Bay Wealth Management LLC purchased a new position in aTyr Pharma during the 4th quarter valued at $25,000. SG Americas Securities LLC purchased a new position in aTyr Pharma during the 1st quarter valued at $55,000. Acadian Asset Management LLC increased its position in aTyr Pharma by 119.6% during the 1st quarter. Acadian Asset Management LLC now owns 45,366 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 24,704 shares during the period. Kingswood Wealth Advisors LLC purchased a new position in aTyr Pharma during the 1st quarter valued at $117,000. Finally, Pale Fire Capital SE increased its position in aTyr Pharma by 425.8% during the 4th quarter. Pale Fire Capital SE now owns 293,706 shares of the biotechnology company’s stock valued at $414,000 after purchasing an additional 237,849 shares during the period. 61.72% of the stock is owned by hedge funds and other institutional investors.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.